KR20180095580A - H-pgds 억제제로서의 퀴놀린-3-카르복스아미드 - Google Patents
H-pgds 억제제로서의 퀴놀린-3-카르복스아미드 Download PDFInfo
- Publication number
- KR20180095580A KR20180095580A KR1020187019904A KR20187019904A KR20180095580A KR 20180095580 A KR20180095580 A KR 20180095580A KR 1020187019904 A KR1020187019904 A KR 1020187019904A KR 20187019904 A KR20187019904 A KR 20187019904A KR 20180095580 A KR20180095580 A KR 20180095580A
- Authority
- KR
- South Korea
- Prior art keywords
- carboxamide
- quinoline
- chloro
- difluoromethoxy
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *c(c(Cl)cc1c2)cc1ncc2C(O)=O Chemical compound *c(c(Cl)cc1c2)cc1ncc2C(O)=O 0.000 description 7
- VIHZKJNXVKTYCA-WKILWMFISA-N C#CCNC(CO[C@H](CC1)CC[C@@H]1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O)=O Chemical compound C#CCNC(CO[C@H](CC1)CC[C@@H]1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O)=O VIHZKJNXVKTYCA-WKILWMFISA-N 0.000 description 1
- SONKNAUWJZBMCR-UHFFFAOYSA-N CC(C(F)F)NC(CC1)CCC1NC(c1cnc(cc(c(Cl)c2)OC(F)F)c2c1)=O Chemical compound CC(C(F)F)NC(CC1)CCC1NC(c1cnc(cc(c(Cl)c2)OC(F)F)c2c1)=O SONKNAUWJZBMCR-UHFFFAOYSA-N 0.000 description 1
- NMWMXVJCCIFFAN-UHFFFAOYSA-N CC(C(F)F)NCC(CC1)CCC1N Chemical compound CC(C(F)F)NCC(CC1)CCC1N NMWMXVJCCIFFAN-UHFFFAOYSA-N 0.000 description 1
- YULZDZYJZQPNJR-WBZWCZPNSA-N CC(C(F)F)NC[C@H](CC1)CC[C@@H]1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O Chemical compound CC(C(F)F)NC[C@H](CC1)CC[C@@H]1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O YULZDZYJZQPNJR-WBZWCZPNSA-N 0.000 description 1
- HSBRVBGGGUNHMP-XOKAFFAESA-N CC(C(F)F)N[C@H](C1)C[C@@H]1N Chemical compound CC(C(F)F)N[C@H](C1)C[C@@H]1N HSBRVBGGGUNHMP-XOKAFFAESA-N 0.000 description 1
- PBIFBAAFCUJLDD-HPKQZAQLSA-N CC(C(F)F)N[C@H](C1)C[C@@H]1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O Chemical compound CC(C(F)F)N[C@H](C1)C[C@@H]1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O PBIFBAAFCUJLDD-HPKQZAQLSA-N 0.000 description 1
- LPQCSEGLHJMMKT-YDRRXPLNSA-N CC(C(F)F)N[C@H](CC1)CC[C@@H]1NC(OCc1ccccc1)=O Chemical compound CC(C(F)F)N[C@H](CC1)CC[C@@H]1NC(OCc1ccccc1)=O LPQCSEGLHJMMKT-YDRRXPLNSA-N 0.000 description 1
- YIHPWULVQBWRRH-UHFFFAOYSA-N CC(C)(C(C1)CC1N)O Chemical compound CC(C)(C(C1)CC1N)O YIHPWULVQBWRRH-UHFFFAOYSA-N 0.000 description 1
- DYKOVMUOYKFJCL-UHFFFAOYSA-N CC(C)(C(N(CC1)CCC1NC(c1cnc(cc(c(Cl)c2)OC(F)F)c2c1)=O)=O)O Chemical compound CC(C)(C(N(CC1)CCC1NC(c1cnc(cc(c(Cl)c2)OC(F)F)c2c1)=O)=O)O DYKOVMUOYKFJCL-UHFFFAOYSA-N 0.000 description 1
- TXRGQHJFGMYIRK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O)=O TXRGQHJFGMYIRK-UHFFFAOYSA-N 0.000 description 1
- HQCNFYPVSUTWSA-JOCQHMNTSA-N CC(C)(C)OC(N[C@H](C1)C[C@@H]1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O)=O Chemical compound CC(C)(C)OC(N[C@H](C1)C[C@@H]1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O)=O HQCNFYPVSUTWSA-JOCQHMNTSA-N 0.000 description 1
- MDBARZYXJRKEAH-WKFQBHICSA-N CC(C)(C)OC(N[C@H](C1)C[C@@]1(C)O)=O Chemical compound CC(C)(C)OC(N[C@H](C1)C[C@@]1(C)O)=O MDBARZYXJRKEAH-WKFQBHICSA-N 0.000 description 1
- DKSMFLTYMRINNK-SHTZXODSSA-N CC(C)([C@H](CC1)CC[C@@H]1NC(c1cnc(cc(C(C)(F)F)c(Cl)c2)c2c1)=O)O Chemical compound CC(C)([C@H](CC1)CC[C@@H]1NC(c1cnc(cc(C(C)(F)F)c(Cl)c2)c2c1)=O)O DKSMFLTYMRINNK-SHTZXODSSA-N 0.000 description 1
- WFONHUGXJBSHTN-HDJSIYSDSA-N CC(C)([C@H](CC1)CC[C@@H]1NC(c1cnc(cc(c(Cl)c2)F)c2c1)=O)O Chemical compound CC(C)([C@H](CC1)CC[C@@H]1NC(c1cnc(cc(c(Cl)c2)F)c2c1)=O)O WFONHUGXJBSHTN-HDJSIYSDSA-N 0.000 description 1
- HFTGFLOKHLVBPJ-IYARVYRRSA-N CC(C)([C@H](CC1)CC[C@@H]1NC(c1cnc(cc(cc2)N3CCC3)c2c1)=O)O Chemical compound CC(C)([C@H](CC1)CC[C@@H]1NC(c1cnc(cc(cc2)N3CCC3)c2c1)=O)O HFTGFLOKHLVBPJ-IYARVYRRSA-N 0.000 description 1
- WNZNTPXKIKSFLZ-UHFFFAOYSA-N CC(C1)(CC1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O)O Chemical compound CC(C1)(CC1NC(c1cnc(cc(c(F)c2)OC(F)F)c2c1)=O)O WNZNTPXKIKSFLZ-UHFFFAOYSA-N 0.000 description 1
- IBACXFSOQYSDIN-UHFFFAOYSA-N CC(CC1)N1c(c(C)cc1c2)cc1ncc2C(O)=O Chemical compound CC(CC1)N1c(c(C)cc1c2)cc1ncc2C(O)=O IBACXFSOQYSDIN-UHFFFAOYSA-N 0.000 description 1
- CFNUZYJDYHHPDI-UHFFFAOYSA-N CC(CC1)N1c(c(Cl)cc1c2)cc1ncc2C(O)=O Chemical compound CC(CC1)N1c(c(Cl)cc1c2)cc1ncc2C(O)=O CFNUZYJDYHHPDI-UHFFFAOYSA-N 0.000 description 1
- PLNAXKOVJPEUQU-VTQGQFRNSA-N CC([C@H](CC1)CC[C@@H]1N)O Chemical compound CC([C@H](CC1)CC[C@@H]1N)O PLNAXKOVJPEUQU-VTQGQFRNSA-N 0.000 description 1
- BLTVVSCQEPONQZ-UHFFFAOYSA-N CC(c(c(Cl)cc1c2)cc1ncc2C(O)=O)=O Chemical compound CC(c(c(Cl)cc1c2)cc1ncc2C(O)=O)=O BLTVVSCQEPONQZ-UHFFFAOYSA-N 0.000 description 1
- RXGDJYGBSUUPCF-UHFFFAOYSA-N CCOC(C1=CN(COCCC(C)C)c2cc(N3CCCC3)c(C)cc2C1=O)=O Chemical compound CCOC(C1=CN(COCCC(C)C)c2cc(N3CCCC3)c(C)cc2C1=O)=O RXGDJYGBSUUPCF-UHFFFAOYSA-N 0.000 description 1
- SYKVMHWPONIGAG-UHFFFAOYSA-N CCOC(c1c[o]c(N(C2)CC2NC(c2cnc(cc(c(F)c3)OC(F)F)c3c2)=O)n1)=O Chemical compound CCOC(c1c[o]c(N(C2)CC2NC(c2cnc(cc(c(F)c3)OC(F)F)c3c2)=O)n1)=O SYKVMHWPONIGAG-UHFFFAOYSA-N 0.000 description 1
- AQOGXRUVTWOVHL-UHFFFAOYSA-N CCOC(c1cc(ccc(OC)c2F)c2nc1)=O Chemical compound CCOC(c1cc(ccc(OC)c2F)c2nc1)=O AQOGXRUVTWOVHL-UHFFFAOYSA-N 0.000 description 1
- BVCZNQFRNUUKKH-UHFFFAOYSA-N CCOC(c1cc(ccc2c3OCC2)c3nc1)=O Chemical compound CCOC(c1cc(ccc2c3OCC2)c3nc1)=O BVCZNQFRNUUKKH-UHFFFAOYSA-N 0.000 description 1
- XWFIDWAEJKDFPF-UHFFFAOYSA-N CCOC(c1cnc(cc(C(C)(C)F)c(Cl)c2)c2c1)=O Chemical compound CCOC(c1cnc(cc(C(C)(C)F)c(Cl)c2)c2c1)=O XWFIDWAEJKDFPF-UHFFFAOYSA-N 0.000 description 1
- NIXIVDPKHYJZNC-UHFFFAOYSA-N CCOC(c1cnc(cc(C(C)(C)O)c(Cl)c2)c2c1)=O Chemical compound CCOC(c1cnc(cc(C(C)(C)O)c(Cl)c2)c2c1)=O NIXIVDPKHYJZNC-UHFFFAOYSA-N 0.000 description 1
- YXTQQENCRGAESR-UHFFFAOYSA-N CCOC(c1cnc(cc(C(C)(F)F)c(Cl)c2)c2c1)=O Chemical compound CCOC(c1cnc(cc(C(C)(F)F)c(Cl)c2)c2c1)=O YXTQQENCRGAESR-UHFFFAOYSA-N 0.000 description 1
- HYBVRMCCEKBQFQ-UHFFFAOYSA-N CCOC(c1cnc(cc(C(C2)C2(F)F)c(F)c2)c2c1)=O Chemical compound CCOC(c1cnc(cc(C(C2)C2(F)F)c(F)c2)c2c1)=O HYBVRMCCEKBQFQ-UHFFFAOYSA-N 0.000 description 1
- CKGJFDZFLRZUNW-UHFFFAOYSA-N CCOC(c1cnc(cc(C2CC2)c(Cl)c2)c2c1)=O Chemical compound CCOC(c1cnc(cc(C2CC2)c(Cl)c2)c2c1)=O CKGJFDZFLRZUNW-UHFFFAOYSA-N 0.000 description 1
- MNONXFSEUGIZCZ-UHFFFAOYSA-N CCOC(c1cnc(cc(c(C)c2)N3C(C)CC3)c2c1)=O Chemical compound CCOC(c1cnc(cc(c(C)c2)N3C(C)CC3)c2c1)=O MNONXFSEUGIZCZ-UHFFFAOYSA-N 0.000 description 1
- XQRIHVPOLQTQIZ-UHFFFAOYSA-N CCOC(c1cnc(cc(cc2)OC(F)(F)F)c2c1Cl)=O Chemical compound CCOC(c1cnc(cc(cc2)OC(F)(F)F)c2c1Cl)=O XQRIHVPOLQTQIZ-UHFFFAOYSA-N 0.000 description 1
- NPJSZMVXZAYSNY-UHFFFAOYSA-N CCOC(c1cnc(cc(cc2)OC(F)F)c2c1)=O Chemical compound CCOC(c1cnc(cc(cc2)OC(F)F)c2c1)=O NPJSZMVXZAYSNY-UHFFFAOYSA-N 0.000 description 1
- ROHZLUWQDJTFSV-WLYNEOFISA-N CN(C)C([C@H](CC1)OC[C@@H]1N)=[U] Chemical compound CN(C)C([C@H](CC1)OC[C@@H]1N)=[U] ROHZLUWQDJTFSV-WLYNEOFISA-N 0.000 description 1
- XZRLBBCAEGZPHV-QZHPEMKGSA-N C[C@@H](C(F)F)/N=C/C(C1)CC1N Chemical compound C[C@@H](C(F)F)/N=C/C(C1)CC1N XZRLBBCAEGZPHV-QZHPEMKGSA-N 0.000 description 1
- HIRXWIJIKRUTSL-QGGXVJLZSA-N C[C@](C1)(C[C@@H]1NC(c1cnc(cc(C2CC2)c(Cl)c2)c2c1)=O)O Chemical compound C[C@](C1)(C[C@@H]1NC(c1cnc(cc(C2CC2)c(Cl)c2)c2c1)=O)O HIRXWIJIKRUTSL-QGGXVJLZSA-N 0.000 description 1
- RQLCWMOVIGTVRA-UHFFFAOYSA-N C[n]1nnnc1N(CC1)CCC1NC(c1cnc(ccc(Cl)c2)c2c1)=O Chemical compound C[n]1nnnc1N(CC1)CCC1NC(c1cnc(ccc(Cl)c2)c2c1)=O RQLCWMOVIGTVRA-UHFFFAOYSA-N 0.000 description 1
- UFGJPHYYSXKROI-KBTIHESUSA-N N[C@H](CC1)CC[C@]1(C(F)F)O Chemical compound N[C@H](CC1)CC[C@]1(C(F)F)O UFGJPHYYSXKROI-KBTIHESUSA-N 0.000 description 1
- JJGNVNPPWDBLAB-SAZUREKKSA-N O=C([C@H](CC1)CC[C@@H]1NC(c1cnc(cc(c(Cl)c2)OC(F)F)c2c1)=O)N1CCOCC1 Chemical compound O=C([C@H](CC1)CC[C@@H]1NC(c1cnc(cc(c(Cl)c2)OC(F)F)c2c1)=O)N1CCOCC1 JJGNVNPPWDBLAB-SAZUREKKSA-N 0.000 description 1
- OLVZTWFALWUMSG-PIJUOVFKSA-N O=C(c1cnc(cc(c(F)c2)OC(F)F)c2c1)N[C@H](CC1)CC1NCC(F)(F)F Chemical compound O=C(c1cnc(cc(c(F)c2)OC(F)F)c2c1)N[C@H](CC1)CC1NCC(F)(F)F OLVZTWFALWUMSG-PIJUOVFKSA-N 0.000 description 1
- FOJJMMWPFNOYCV-OCCSQVGLSA-N O=C(c1cnc(cc(cc2)OC(F)F)c2c1)N[C@H]1CO[C@H](CC(F)(F)F)CC1 Chemical compound O=C(c1cnc(cc(cc2)OC(F)F)c2c1)N[C@H]1CO[C@H](CC(F)(F)F)CC1 FOJJMMWPFNOYCV-OCCSQVGLSA-N 0.000 description 1
- GGYSULYEXLODNB-UHFFFAOYSA-N OC(c1cnc(cc(C(C2)C2(F)F)c(Cl)c2)c2c1)=O Chemical compound OC(c1cnc(cc(C(C2)C2(F)F)c(Cl)c2)c2c1)=O GGYSULYEXLODNB-UHFFFAOYSA-N 0.000 description 1
- URTGQWBRVWYGML-UHFFFAOYSA-N OC(c1cnc(cc(C2CC2)c(Cl)c2)c2c1)=O Chemical compound OC(c1cnc(cc(C2CC2)c(Cl)c2)c2c1)=O URTGQWBRVWYGML-UHFFFAOYSA-N 0.000 description 1
- XLFKROZZWIYLNS-UHFFFAOYSA-N OC(c1cnc(cc(C2CC2)c(F)c2)c2c1)=O Chemical compound OC(c1cnc(cc(C2CC2)c(F)c2)c2c1)=O XLFKROZZWIYLNS-UHFFFAOYSA-N 0.000 description 1
- VWJGTDXADNDFLG-UHFFFAOYSA-N OCC(C(F)(F)F)NC(CC1)CCC1NC(c1cnc(cc(c(Br)c2)OC(F)F)c2c1)=O Chemical compound OCC(C(F)(F)F)NC(CC1)CCC1NC(c1cnc(cc(c(Br)c2)OC(F)F)c2c1)=O VWJGTDXADNDFLG-UHFFFAOYSA-N 0.000 description 1
- DFGFFUYCKDYLIN-UHFFFAOYSA-M [O-]C(c1cc(cc(c(OC(F)F)c2F)Cl)c2nc1)=O Chemical compound [O-]C(c1cc(cc(c(OC(F)F)c2F)Cl)c2nc1)=O DFGFFUYCKDYLIN-UHFFFAOYSA-M 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268630P | 2015-12-17 | 2015-12-17 | |
| US62/268,630 | 2015-12-17 | ||
| PCT/IB2016/057676 WO2017103851A1 (en) | 2015-12-17 | 2016-12-15 | Quinoline-3-carboxamides as h-pgds inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180095580A true KR20180095580A (ko) | 2018-08-27 |
Family
ID=57589094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187019904A Withdrawn KR20180095580A (ko) | 2015-12-17 | 2016-12-15 | H-pgds 억제제로서의 퀴놀린-3-카르복스아미드 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210238162A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3390384B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019502691A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180095580A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108430992A (cg-RX-API-DMAC7.html) |
| AR (1) | AR107044A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016370779B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018012469B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3008358A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2018126105A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201733988A (cg-RX-API-DMAC7.html) |
| UY (1) | UY37028A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017103851A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ. ホフマン-ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| MY196327A (en) | 2016-11-11 | 2023-03-24 | Bayer Animal Health Gmbh | New Anthelmintic Quinoline-3-Carboxamide Derivative |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| WO2018195123A1 (en) | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US11149035B2 (en) | 2017-06-13 | 2021-10-19 | Glaxosmithkline Intellectual Property Dfvelopment Limited | Chemical compounds as H—PGDS inhibitors |
| US11254661B2 (en) | 2017-08-04 | 2022-02-22 | Bayer Animal Health Gmbh | Quinoline derivatives for treating infections with helminths |
| TW201920129A (zh) | 2017-09-01 | 2019-06-01 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| US20210139507A1 (en) * | 2017-12-13 | 2021-05-13 | Glaxosmithkline Intellectual Property Development Limited | Fused pyridines which act as inhibitors of h pgds |
| MX2020006185A (es) | 2017-12-15 | 2020-09-03 | Bayer Animal Health Gmbh | Proceso para la preparacion de derivados de quinolina. |
| CN112313208B (zh) * | 2018-04-17 | 2024-04-19 | 泰普斯特医疗公司 | 双环羧酰胺及其使用方法 |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| CN112074514B (zh) | 2018-05-09 | 2024-10-29 | 礼蓝动物保健有限公司 | 新的喹啉衍生物 |
| US20220177456A1 (en) * | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2021204930A1 (en) | 2020-04-09 | 2021-10-14 | Bayer Animal Health Gmbh | Substituted condensed azines as anthelmintic compounds |
| CN111549000B (zh) * | 2020-06-18 | 2022-07-29 | 中国医学科学院整形外科医院 | 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用 |
| JP7734129B2 (ja) | 2020-06-19 | 2025-09-04 | 佐藤製薬株式会社 | H-pgdsを阻害する縮環化合物 |
| MX2023002947A (es) * | 2020-09-11 | 2023-06-06 | Univ California | Composiciones y métodos para el tratamiento de distrofias musculares. |
| CA3217271A1 (en) * | 2021-05-28 | 2022-12-01 | Yonggang Chen | Synthesis of btk inhibitor and intermediates thereof |
| EP4148052A1 (en) | 2021-09-09 | 2023-03-15 | Bayer Animal Health GmbH | New quinoline derivatives |
| CA3240926A1 (en) | 2021-12-17 | 2023-06-22 | Sato Pharmaceutical Co., Ltd. | Azaindole derivative inhibiting h-pgds |
| CN117562559A (zh) * | 2023-12-04 | 2024-02-20 | 东华大学 | 基于功率和力矩输出的上臂肱二头肌疲劳识别与预测方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100321649B1 (ko) | 1993-03-17 | 2002-07-22 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제 |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| CH1196397H1 (de) * | 1999-06-02 | 2007-05-31 | Nps Pharma Inc | Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems. |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| WO2005094805A1 (ja) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンd合成酵素を阻害するピリミジン化合物 |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用 |
| NZ579892A (en) | 2007-03-30 | 2012-03-30 | Sanofi Aventis | Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| EP2231666B1 (en) * | 2007-12-12 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| EP2307378A1 (en) * | 2008-06-18 | 2011-04-13 | Pfizer Limited | Nicotinamide derivatives |
| EP2307377A1 (en) | 2008-06-18 | 2011-04-13 | Pfizer Limited | Nicotinamide derivatives |
| MY154000A (en) | 2008-09-22 | 2015-04-30 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN102341385B (zh) | 2009-03-09 | 2014-01-15 | 大鹏药品工业株式会社 | 能够抑制前列腺素d合酶的哌嗪化合物 |
| WO2011043359A1 (ja) | 2009-10-06 | 2011-04-14 | 協和発酵キリン株式会社 | 芳香族複素環化合物を含有する医薬 |
| CA2776242C (en) | 2009-10-08 | 2014-09-02 | Sanofi | Phenyloxadiazole derivatives as pgds inhibitors |
| JP5677325B2 (ja) | 2010-01-22 | 2015-02-25 | 大鵬薬品工業株式会社 | Pgds阻害作用を有するピペラジン化合物 |
| US9212209B2 (en) * | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
-
2016
- 2016-12-15 AU AU2016370779A patent/AU2016370779B2/en not_active Expired - Fee Related
- 2016-12-15 WO PCT/IB2016/057676 patent/WO2017103851A1/en not_active Ceased
- 2016-12-15 KR KR1020187019904A patent/KR20180095580A/ko not_active Withdrawn
- 2016-12-15 AR ARP160103847A patent/AR107044A1/es unknown
- 2016-12-15 CN CN201680074158.0A patent/CN108430992A/zh active Pending
- 2016-12-15 UY UY0001037028A patent/UY37028A/es unknown
- 2016-12-15 TW TW105141512A patent/TW201733988A/zh unknown
- 2016-12-15 CA CA3008358A patent/CA3008358A1/en not_active Abandoned
- 2016-12-15 RU RU2018126105A patent/RU2018126105A/ru not_active Application Discontinuation
- 2016-12-15 BR BR112018012469-9A patent/BR112018012469B1/pt not_active IP Right Cessation
- 2016-12-15 JP JP2018531378A patent/JP2019502691A/ja active Pending
- 2016-12-15 US US16/062,223 patent/US20210238162A1/en not_active Abandoned
- 2016-12-15 EP EP16815960.6A patent/EP3390384B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019502691A (ja) | 2019-01-31 |
| UY37028A (es) | 2017-07-31 |
| WO2017103851A1 (en) | 2017-06-22 |
| EP3390384A1 (en) | 2018-10-24 |
| AR107044A1 (es) | 2018-03-14 |
| AU2016370779A1 (en) | 2018-06-14 |
| TW201733988A (zh) | 2017-10-01 |
| EP3390384B1 (en) | 2021-09-15 |
| BR112018012469B1 (pt) | 2020-11-24 |
| US20210238162A1 (en) | 2021-08-05 |
| BR112018012469A2 (pt) | 2018-12-18 |
| CA3008358A1 (en) | 2017-06-22 |
| RU2018126105A (ru) | 2020-01-17 |
| CN108430992A (zh) | 2018-08-21 |
| AU2016370779B2 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016370779B2 (en) | Quinoline-3-carboxamides as H-PGDS inhibitors | |
| JP6938628B2 (ja) | 造血器型プロスタグランジンdシンターゼ阻害剤としての1,3二置換シクロブタンまたはアゼチジン誘導体 | |
| EP3256463B1 (en) | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists | |
| US9550777B2 (en) | 3-substituted pyrazoles and use as DLK inhibitors | |
| TW202136250A (zh) | 蛋白質酪胺酸磷酸酶降解劑及其使用方法 | |
| CN112236423B (zh) | 哌啶基-3-(芳氧基)丙酰胺和丙酸酯 | |
| JP6611358B2 (ja) | 癌治療のためのfasn阻害剤として有用なベンズアミド誘導体 | |
| RS58892B1 (sr) | Jedinjenja 3-aminocikloalkila kao inhibitori ror-gama-t i njihove upotrebe | |
| CA2917193A1 (en) | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators | |
| US20230203007A1 (en) | Pyridinylacetamide derivatives as sodium channel activators | |
| CN115380030B (zh) | 作为sstr4激动剂的n-杂芳基烷基-2-(杂环基和杂环基甲基)乙酰胺衍生物 | |
| TW202039479A (zh) | 化合物 | |
| KR20230017796A (ko) | Tlr2 조절제 화합물, 약제학적 조성물 및 이들의 용도 | |
| JP2022547427A (ja) | 置換1,3-フェニルヘテロアリール誘導体及び疾患の治療におけるその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180712 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |